INNOVATION COMMERCIALISATION ACTIVITYArranging signing and transfer of License of genetically modified mice (5-HTT, PAC1, VIPR2 transgenic mice and Vipr2 knockout mice) from UK MRC to NUIG;VIPR2 YAC transgenic mice � under negotiation for licensing to a major Pharma company;Filed an Invention Disclosure (IDF) on �The generation of human induced pluripotent stem cells with genetic alteration of NRXN1 gene� at the NUI Galway in Jan 2013;Filed an Invention Disclosure (IDF) on �The generation of human induced pluripotent stem cells with genetic alteration of FMR1 gene� at the NUI Galway in Jan 2013;Initiated collaborations and engaged Eli Lilly on SFI IvP application to create NRXN1 iPSC lines as disease model for autism and schizophrenia;Involved in a Pfizer-funded 4M Grand Challenge Neuroscience collaboration project (09 10-08 13) with 7 UK institutions, centered on Disc1tr mice I made;Collaborated with Wyeth TMRI Ltd to phenotype Disc1tr mice with 2 research grants.